ShedRx vs Vaylen
Two GLP-1 providers, one scoreboard. We put ShedRx and Vaylen head-to-head on the published Brief Score — the same six factors, scored the same way.
The verdict
Too close to call on the Brief Score.
ShedRx and Vaylen are level at 87/100. The scores won't separate them, so the pick comes down to fit: ShedRx for readers who want an oral or sublingual option, or one of the lower tirzepatide prices on the tracker. Vaylen for readers who want brand, compounded and oral options from one accredited nationwide provider without a premium sticker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| ShedRx | Vaylen | |
|---|---|---|
| Brief Score | 87/100 (B+) | 87/100 (B+) |
| Semaglutide | $199/mo on the 1-month plan · $179/mo on 6 months · $159/mo only on a 12-month commitment (all plans carry a 2-month minimum) | $179/mo |
| Tirzepatide | $299/mo on the 1-month plan · $269/mo on 6 months · $239/mo only on a 12-month commitment (all plans carry a 2-month minimum) | $239/mo |
| Coverage | Not disclosed | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Yes |
| On the tracker | Fallingprice falling | Stableprice stable |
ShedRx: Its lowest tirzepatide rate is $239, and that needs the 12-month commitment; the one-month rung is $299.
Vaylen: $179 sema / $239 tirz; brand + oral + LegitScript across all 50 states.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.